Biogen (BIIB) to Release Quarterly Earnings on Tuesday

Biogen (NASDAQ:BIIB) is projected to post its quarterly earnings results before the market opens on Tuesday, February 11th. Analysts expect Biogen to post earnings of $3.43 per share and revenue of $2.42 billion for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Biogen Stock Performance

Shares of BIIB opened at $141.35 on Monday. Biogen has a one year low of $139.71 and a one year high of $244.95. The company has a 50-day simple moving average of $149.14 and a two-hundred day simple moving average of $175.79. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The firm has a market capitalization of $20.60 billion, a PE ratio of 12.77, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BIIB shares. Wolfe Research began coverage on Biogen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Mizuho reduced their target price on shares of Biogen from $251.00 to $207.00 and set an “outperform” rating on the stock in a research report on Thursday, November 21st. Needham & Company LLC lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $270.00 price target for the company. in a research note on Monday, November 18th. Wells Fargo & Company dropped their price objective on shares of Biogen from $190.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Friday, January 10th. Finally, Stifel Nicolaus downgraded shares of Biogen from a “buy” rating to a “hold” rating and set a $175.00 target price for the company. in a research note on Monday, December 16th. Sixteen equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $228.80.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.